Six month follow-up results and retreatment rates with the Supracor LASIK procedure for presbyopia
Session Details
Session Title: Presbyopia Correction
Session Date/Time: Tuesday 13/09/2016 | 16:00-18:00
Paper Time: 16:18
Venue: Auditorium A
First Author: : K.Liesto FINLAND
Co Author(s): : J. Rinta-Rahko
Abstract Details
Purpose:
To evaluate the six month post-operative data and strategies to reduce retreatment rates in hyperopic presbyopic patients undergoing a varifocal LASIK procedure.
Setting:
Mehilainen, Helsinki, Finland
Methods:
A single centre evaluation on 112 hyperopic presbyopes treated with the Supracor LASIK procedure (Bausch + Lomb Technolas). All flap procedures were performed with a Femto-lasik procedure (Visumax-femto) and ablation with the excimer laser (Technolas 217z100). Of these hyperopic patients 81 underwent a bilateral mild Supracor LASIK treatment in the dominant eye and a regular treatment in the non-dominant eye. The target refraction was +-0/ -0.5D respectively.
Results:
Mean patient age was 54.5 years. Pre-operative spherical equivalent (SE), sphere and cylinder were 1.71D, 1.92D and -0.43D, respectively. At 6 months post-op in the mild treated eyes, SE, sphere and cylinder were -0.02D, 0.07D and -0.18D. All patients achieved monocular BCDVA of 0.8 decimal or better and 93% had 1.0 decimal. 84.4% had monocular UDVA of 0.8 decimal or better, providing good far vision. 70% patients achieved UNVA of J3 or better with regular treatment, providing good near vision. 54% had UDVA of 0.8 or better in this group. 7 patients needed unilateral retreatment and one bilateral. Further strategies on Supracor mild/regular combination will be presented.
Conclusions:
In our opinion, Supracor provides a good balance between distance visual acuity and good near vision when using the Supracor mild procedure in the dominant and regular in the non-dominant eye. In our hands, Supracor LASIK is superior to the monovision procedure. Our approach involves careful preoperative examinations, always full cycloplegic refractive correction to avoid latent untreated hyperopia and targeting the centre of photopic pupil to utilize 100% of the Supracor power.
Financial Disclosure:
NONE